Mycoplasma genitalium (MG) is one of the fastest growing STIs in the world and has been reported to have a higher incidence than gonorrhea. It has developed serious treatment challenges due to rising antibiotic resistance. With macrolide resistance levels exceeding 50 percent in some settings, the new test will significantly improve patient management, allowing physicians to immediately select the optimal treatment.
SpeeDx CEO Colin Denver said,”ResistancePlus MG is the first and only known diagnostic test that can simultaneously detect MG and identify macrolide resistance. TGA approval will allow our world-leading diagnostic technology to be put to use here in Australia to help medical professionals address the serious public health challenge of MG while improving clinical outcomes for patients confronted by the challenge of antibiotic-resistant sexually transmitted infections.”